RxDoctor Payments Data

Dwight Faught

Psychiatric/Mental Health · Mesa, AZNPI 1093050494

Payments from drug & device makers

$945in general payments, 2019–2025

Across 38 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$399
  • Teva Pharmaceuticals USA, Inc.$189
  • Indivior Inc.$86
  • Alkermes, Inc.$85
  • AbbVie$74
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$89695%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$945 in reported general payments places this provider in the 65th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$10,602
Medicare patients
29
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate28$249,607
Invega SustennaPaliperidone Palmitate64$185,953
Abilify MaintenaAripiprazole30$89,088
PerserisRisperidone13$39,136
AristadaAripiprazole Lauroxil11$36,808
Lurasidone Hcl84$13,849
Aripiprazole143$7,562
Clozapine96$6,160
Fluphenazine Hcl15$6,026
Divalproex Sodium ErDivalproex Sodium72$4,922
Olanzapine121$4,153
Fluphenazine Decanoate33$4,052
Quetiapine Fumarate221$3,977
Bupropion XlBupropion Hcl212$3,949
Hydroxyzine Hcl112$3,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$17$185,95364 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$399$89,08830 claims
Indivior Inc.Perseris$86$39,13613 claims
Alkermes, Inc.Aristada$85$36,80811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →